TD Cowen analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $35.00.

TD Cowen analyst Bryan Bergin upgraded Genpact (G) to Buy from Hold with a price target of $60, up from $45. The company’s turnaround traction ...

The discount of Western Canada Select (WCS) heavy crude to the North American benchmark West Texas Intermediate futures (WTI) narrowed slightly on Thursday: * WCS for March delivery in Hardisty, ...

Apple supplier Skyworks Solutions saw its stock drop nearly 25% Thursday as the semiconductor firm said that it's losing ...

TD Cowen analysts view Sen. Dan Sullivan’s proposed missile defense legislation as a long-term catalyst for major U.S. defense contractors, with Lockheed Martin (NYSE:LMT), Northrop Grumman (NYSE:NOC) ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

TD Cowen analysts upheld their positive stance on BJ's Wholesale (NYSE:BJ) with a reaffirmed Buy rating and a steady price target of $115.00. The brokerage firm's analysts project a favorable outlook ...

Seeing “growth on hiatus,” Mr. Bir reduced his own forecast for 2025 and 2026 “with revisions mainly for longer lease-up ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics ...